Viral haemorrhagic fevers
Authors:
M. Trojánek 1,2; H. Roháčová 1,2; V. Marešová 1,2; Stejskal F. 1–4
Authors place of work:
Infekční klinika 2. LF UK a Nemocnice Na Bulovce, Praha
Přednosta: doc. MUDr. Dušan Pícha, CSc.
1; Klinika infekčních, parazitárních a tropických nemocí Nemocnice Na Bulovce, Praha
Primář: MUDr. Hana Roháčová, PhD.
2; Infekční oddělení, Krajská nemocnice Liberec
Primář: MUDr. Adam Vitouš
3; Ústav imunologie a mikrobiologie 1. LF UK a VFN, Praha
Přednostka: prof. RNDr. Libuše Kolářová, CSc.
4
Published in the journal:
Prakt. Lék. 2015; 95(1): 4-11
Category:
Reviews
Summary
Viral haemorrhagic fevers are caused by enveloped RNA viruses that belong to the families Filoviridae (Ebola, Marburg), Arenaviridae (Lassa, Lujo, Junin, Machupo, Guanarito), Bunyaviridae (hantaviruses, Crimean-Congo haemorrhagic fever and Rift Valley fever virus) and Flaviviridae (yellow fever, Omsk haemorrhagic fever virus). These infections manifest as acute systemic febrile illnesses with severe clinical course followed by development of shock syndrome and subsequent multiorgan dysfunction syndrome. Viral haemorrhagic fevers are widespread and present in all continents with the exception of Antarctica and represent typical zoonotic infections with natural foci. The potential for direct human-to-human transmission is significant in Lassa, Ebola, Marburg and Crimean-Congo haemorrhagic fevers. Although the risk of transmission to tourists is relatively low, these infections are feared for their severe clinical course and unavailable specific treatment. Current Ebola outbreak in western Africa shows that these infections represent a significant public health problem. The potential risk represents the use of these pathogens as weapons of mass destruction. Provision of medical care for patients with viral haemorrhagic fever should be restricted to specialized centres.
Keywords:
viral haemorrhagic fevers – tropical medicine – Ebola – Lassa – Crimean-Congo haemorrhagic fever – vaccination
Zdroje
1. Atkin S, Anakari S, Gothard P, et al. The first case of Lassa fever imported from Mali to the United Kingdom, February 2009. Euro Surveill 2009; 14(10): 1–3.
2. Baize S, Pannetier D, Oestereich L, et al. Emergence of Zaire Ebola virus disease in Guinea-preliminary report. N Engl J Med 2014; 371(15): 1418–1425.
3. Bausch DG, Schwar, L. Outbreak of ebola virus disease in Guinea: where ecology meets economy. PLoS Negl Trop Dis 2014; 8(7), e3056.
4. Bausch DG. Viral hemorrhagic fevers. In D. Schlossberg et al. Clinical Infectious Diseases. 1st Ed. New York: Cambridge University Press 2008; 1319–1332.
5. Beeching NJ, Fletcher TE, Hill DR, Thomson GL. Travellers and viral haemorrhagic fevers: what are the risks? Int J Antimicrob Agents 2010; 36(Suppl 1): S26–35.
6. Dobler G. Zoonotic tick-borne flaviviruses. Vet Microbio, 2010; 140(3–4): 221–228.
7. Dong J, Olano JP, McBride JW. Emerging pathogens: challenges and successes of molecular diagnostics. J Mol Diagn 2008; 10(3): 185–197.
8. Ergonul O. Crimean-Congo hemorrhagic fever virus: new outbreaks, new discoveries. Curr Opin Virol 2012; 2(2): 215–220.
9. Ftika L, Maltezou HC. Viral haemorrhagic fevers in healthcare settings, J Hosp Infect 2013; 83(3): 185–192.
10. Gomez RM, Jaquenod de Giusti C, Sanchez Vallduvi MM, et al. Junin virus. A XXI century update. Microbes Infect 2011; 13(4): 303–311.
11. Gubler DJ. The changing epidemiology of yellow fever and dengue, 1900 to 2003: full circle? Comp Immunol Microbiol Infect Dis 2004; 27(5): 319–330.
12. Guerrant RL, Walker DH, Weller PF, et al. Tropical infectious diseases: principles and practice. 3rd Ed. New York: Saunders 2011.
13. Holbrook MR. Kyasanur forest disease. Antiviral Res 2012; 96(3): 353–362.
14. Charrel RN, Coutard B, Baronti C. Arenaviruses and hantaviruses: from epidemiology and genomics to antivirals. Antiviral Res 2011; 90(2): 102–114.
15. Charrel RN, de Lamballerie X. Arenaviruses other than Lassa virus. Antiviral Res 2003; 57(1–2): 89–100.
16. Ikegami T, Makino S. The pathogenesis of Rift Valley fever. Viruses 2011; 3(5): 493–519.
17. Ippolito G, Feldmann H, Lanini S, et al. Viral hemorrhagic fevers: advancing the level of treatment. BMC Med 2012; 10(31): 1–8.
18. Isaacson M. Viral hemorrhagic fever hazards for travelers in Africa. Clin Infect Dis 2001; 33(10): 1707–1712.
19. Kanapathipillai R, Restrepo AM, Fast P, et al. Ebola vaccine - an urgent international priority. N Engl J Med 2014 [on line] 2014-10-07 [cit. 2014-10-15]. Dostupné z: http://www.nejm.org/doi/full/10.1056/NEJMp1412166.
20. Kondratowicz AS, Maury WJ. Ebolavirus: a brief review of novel therapeutic targets. Future Microbiol 2012; 7(1): 1–4.
21. Kortepeter MG, Bausch DG, Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis 2011; 204(Suppl 3): S810–816.
22. Leroy EM, Gonzalez JP, Baize S. Ebola and Marburg haemorrhagic fever viruses: major scientific advances, but a relatively minor public health threat for Africa. Clin Microbiol Infect 2011; 17(7): 964–976.
23. Mackenzie JS, Gubler DJ, Petersen LR. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 2004; 10(Suppl 12): S98–109.
24. MacNeil A, Rollin PE. Ebola and Marburg hemorrhagic fevers: neglected tropical diseases? PLoS Negl Trop Dis 2012; 6(6):, e1546.
25. Mahanty S, Bray M. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 2004; 4(8): 487–498.
26. Maltezou HC, Papa A. Crimean-Congo hemorrhagic fever: risk for emergence of new endemic foci in Europe? Travel Med Infect Dis 2010; 8(3): 139–143.
27. Manigold T, Vial P. Human hantavirus infections: epidemiology, clinical features, pathogenesis and immunology. Swiss Med Wkly 2014; 144, w13937 [on line] [cit. 2014-09-15]. Dostupné na: http://www.smw.ch/scripts/stream_pdf.php?doi=smw-2014-13937.
28. Memish ZA, Fagbo SF, Assiri AM, et al. Alkhurma viral hemorrhagic fever virus: proposed guidelines for detection, prevention, and control in Saudi Arabia. PLoS Negl Trop Dis 2012; 6(7): e1604.
29. Ministerstvo zdravotnictví ČR. Minimální a optimální vybavení ordinací VPL proti vysoce nebezpečným infekcím [on line] [cit. 2014-10-11]. Dostupné na: http://www.svl.cz/files/files/Zpravy/42761_OOPP.pdf
30. Ministerstvo zdravotnictví ČR. Směrnice pro jednotný postup při vzniku mimořádné události podléhající Mezinárodním zdravotnickým předpisům v souvislosti s výskytem vysoce nakažlivé nemoci ve zdravotnickém zařízení [on line] [cit. 2014-08-15]. Dostupné na: http://www.mzcr.cz/Verejne/obsah/smernice-pro-zdravotnicka-zarizeni_2879_5.html.
31. Ogbu O, Ajuluchukwu E, Uneke CJ. Lassa fever in West African sub-region: an overview. J Vector Borne Dis 2007; 44(1): 1–11.
32. Richmond JK, Baglole DJ. Lassa fever: epidemiology, clinical features, and social consequences. BMJ 2003; 327(7426): 1271–1275.
33. Roddy P, Howard N, Van Kerkhove MD, et al. Clinical manifestations and case management of Ebola haemorrhagic fever caused by a newly identified virus strain, Bundibugyo, Uganda 2007–2008. PLoS One 2012; 7(12): e52986.
34. Ruzek D, Yakimenko VV, Karan LS, et al. Omsk haemorrhagic fever. Lancet 2010; 376(9758): 2104–2113.
35. Solomon T, Thomson G. Viral haemorrhagic fevers. In Cook G, Zumla A. (eds.) Manson’s Tropical Diseases. 22nd Ed., New York: Saunders 2009; 763–785.
36. Vaheri A, Henttonen H, Voutilainen L, et al. Hantavirus infections in Europe and their impact on public health. Rev Med Virol 2013; 23(1): 35–49.
37. Weaver SC, Reisen WK. Present and future arboviral threats. Antiviral Res 2010; 85(2): 328–345.
38. World Health Organization. Global alert and response, diseases outbreak news [on line] [cit. 2014-10-11]. Dostupné na: http://www.who.int/csr/don/en/
39. World Health Organization. Potential new Ebola therapies and vaccines – background document [on line] [cit. 2014-10-11]. Dostupné z: http://www.who.int/csr/disease/ebola/ebola-new-interventions-02-sep-2014.pdf?ua=1
40. Yilmaz GR, Buzgan T, Irmak H, et al. The epidemiology of Crimean-Congo hemorrhagic fever in Turkey, 2002-2007. Int J Infect Dis 2009; 13(3): 380–386.
Štítky
General practitioner for children and adolescents General practitioner for adultsČlánok vyšiel v časopise
General Practitioner
2015 Číslo 1
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Memantine Eases Daily Life for Patients and Caregivers
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
Najčítanejšie v tomto čísle
- Current treatment of liver abscess – Experience of Surgical Clinic of University Hospital Pilsen
- Clostridial phlegmona of the abdominal wall in an obese patient with Crohn’s disease
- Viral haemorrhagic fevers
- The impact of the holocaust on the health of survivors